StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine,
“Regeneration-Inducing Medicine™”.
| November 13, 2024 | Timely Disclosure Information | StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock |
|---|---|---|
| November 05, 2024 | Timely Disclosure Information | StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide |
| October 31, 2024 | Timely Disclosure Information | Presentation Material for Business Plan and Growth Potential |
| September 25, 2024 | Timely Disclosure Information | Notice Regarding Appointment of Director Candidates |
| September 25, 2024 | Timely Disclosure Information | StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators |
| April 25, 2023 | NEWS Release |
|---|
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine™”.
“Regeneration-Inducing Medicine™” is an innovative new class of medicine that induces functional regeneration of tissues and organs in the patient's body by maximizing the human body's innate ability of tissue repairing.
We are pursuing research and development of new drugs based on a novel mechanism of action leading to recruitment of the patients’ own in-vivo stem cells to the damaged tissues for functional tissue regeneration without conventional cell-therapy approaches.
